カテゴリ： GlobalData, シンガポール, 企業調査

Aslan Pharmaceuticals Pte Ltd (6497)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Aslan Pharmaceuticals Pte Ltd (6497) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10647
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：65
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：シンガポール
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Aslan Pharmaceuticals Pte Ltd (Aslan), a subsidiary of Aslan Pharmaceuticals Ltd, is a biotechnology company that offers immuno-oncology agents and targeted therapies. The company’s pipeline products comprise varlitinib, ASLAN002, ASLAN003 and ASLAN004. Its ASLAN002 is a small molecule inhibitor of RON and cMET receptor tyrosine kinases for the treatment of gastric and breast cancer. Aslan’s ASLAN003 is a small molecule inhibitor of dihydroorotate dehydrogenase inhibitor to treat tumors; and ASLAN004 is a full human monoclonal antibody that reduces exacerbation in moderate or severe asthma and improves the functioning of lungs. It operates in Singapore, Taiwan, China and Australia. Aslan is headquartered in Singapore City, Singapore.

Aslan Pharmaceuticals Pte Ltd (6497) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Aslan Pharma Raises USD23 Million in Venture Financing 12
Aslan Pharma Raises Additional USD9 Million in Venture Financing 14
Aslan Pharma Raises USD34 Million in Series C Financing 16
Aslan Pharma Raises US$22 Million In Series B Financing 18
Partnerships 20
Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 20
Aslan Pharma Enters into MoU with National Cancer Centre Singapore 21
ASLAN Pharma Enters into Agreement with ACT Genomics 22
Licensing Agreements 23
Aslan Pharma Enters into Licensing Agreement with Array BioPharma 23
ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 24
ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 25
Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 26
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 27
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 28
Equity Offering 29
Aslan Pharma Raises USD42.2 Million in Public Offering of Shares 29
Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31
Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32
Aslan Pharma Raises USD33.2 Million in IPO 33
Aslan Pharmaceuticals Pte Ltd – Key Competitors 34
Aslan Pharmaceuticals Pte Ltd – Key Employees 35
Aslan Pharmaceuticals Pte Ltd – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Aug 06, 2018: Aslan pharmaceuticals reports second quarter 2018 financial results and provides corporate update 37
Corporate Communications 38
Jan 23, 2017: Aslan Pharmaceuticals Receives Approval To List On Taipei Exchange 38
Product News 39
08/31/2017: ASLAN Pharmaceuticals Announces First Patient Enrolled in a Global Phase 2/3 Study for Varlitinib in Gastric Cancer 39
08/10/2018: ASLAN Pharmaceuticals completes recruitment for global phase 2 study for Varlitinib in first line gastric cancer 40
05/17/2018: ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO 41
01/31/2018: ASLAN Pharmaceuticals sponsors Cholangiocarcinoma Foundation Annual Conference 2018 42
01/24/2017: Aslan Pharmaceuticals To Present At The Cholangiocarcinoma Foundation Annual Conference 2017 43
01/18/2018: ASLAN Pharmaceuticals Appoints Stephen Doyle as Head of China 44
Product Approvals 45
Aug 20, 2018: ASLAN Pharmaceuticals granted Orphan Drug Designationby the FDA for ASLAN003 for the treatment of acute myeloid leukaemia 45
Feb 19, 2017: ASLAN Pharmaceuticals receives Orphan Drug Designation in Korea for varlitinib (ASLAN001) in biliary tract cancer 46
Clinical Trials 47
Oct 09, 2018: Aslan Pharmaceuticals to present poster on Varlitinib at European Society for Medical Oncology congress 47
Sep 17, 2018: ASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China 48
Jul 03, 2018: Aslan Pharmaceuticals Submits Clinical Trial Authorisation Application For First In Man Studies For ASLAN004 49
Apr 17, 2018: ASLAN Pharmaceuticals Announces Presentation of New Pre-Clinical Data on Varlitinib in Hepatocellular Carcinoma at AACR 50
Jan 08, 2018: ASLAN Pharmaceuticals announces shortened timeline to commercialisation for varlitinib in China 51
Jan 02, 2018: Aslan Pharmaceuticals Abstract On Varlitinib Wins Best Poster At ESMO Asia 2017 52
Nov 13, 2017: Aslan Pharmaceuticals Receives IND Approval In Singapore To Initiate Phase 2 Study Of ASLAN003 In Acute Myeloid Leukaemia 53
Nov 08, 2017: ASLAN Pharmaceuticals Announces Poster Presentation at ESMO Asia Congress 2017 54
Sep 07, 2017: Aslan Pharmaceuticals Announces Initiation Of First Clinical Study In Hepatocellular Carcinoma For Varlitinib 55
Jun 29, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Global Pivotal Treetopp Study For Varlitinib In Biliary Tract Cancer 56
Jun 12, 2017: Aslan Pharmaceuticals Announces MTD For Varlitinib In Combination With Chemotherapies Commonly Used In First Line Gastric Cancer 57
Jun 07, 2017: Aslan Pharmaceuticals Announces New Positive Data Identifying ASLAN003 As A Novel Therapeutic Agent In Acute Myeloid Leukaemia 58
Jun 02, 2017: Aslan Pharmaceuticals Announces Publication of New Varlitinib Data in Metastatic Solid Tumours at ASCO 59
Jun 01, 2017: Aslan Pharmaceuticals Receives Clinical Trial Authorisation To Initiate Pivotal Study Of Varlitinib In Gastric Cancer 60
May 18, 2017: New Data On Varlitinib Published At 2017 Annual Meeting Of American Society Of Cancer Oncology 61
Apr 25, 2017: ASLAN Pharmaceuticals Initiates Global Pivotal Study For Varlitinib In Biliary Tract Cancer 62
Feb 13, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Phase 1 Study Of Varlitinib In Japan 63
Feb 09, 2017: ASLAN Pharmaceuticals reports positive top-line results for phase 2 clinical trial of varlitinib in metastatic breast cancer 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aslan Pharmaceuticals Pte Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aslan Pharma Raises USD23 Million in Venture Financing 12
Aslan Pharma Raises Additional USD9 Million in Venture Financing 14
Aslan Pharma Raises USD34 Million in Series C Financing 16
Aslan Pharma Raises US$22 Million In Series B Financing 18
Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 20
Aslan Pharma Enters into MoU with National Cancer Centre Singapore 21
ASLAN Pharma Enters into Agreement with ACT Genomics 22
Aslan Pharma Enters into Licensing Agreement with Array BioPharma 23
ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 24
ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 25
Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 26
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 27
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 28
Aslan Pharma Raises USD42.2 Million in Public Offering of Shares 29
Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31
Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32
Aslan Pharma Raises USD33.2 Million in IPO 33
Aslan Pharmaceuticals Pte Ltd, Key Competitors 34
Aslan Pharmaceuticals Pte Ltd, Key Employees 35
Aslan Pharmaceuticals Pte Ltd, Other Locations 36
Aslan Pharmaceuticals Pte Ltd, Subsidiaries 36

List of Figures
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Aslan Pharmaceuticals Pte Ltd (6497)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Ypsomed Holding AG (YPSN)
    Ypsomed Holding AG (YPSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Pilgrim’s Pride Corp (PPC)：企業の財務・戦略的SWOT分析
    Pilgrim's Pride Corp (PPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Linamar Corporation (LNR)：企業の財務・戦略的SWOT分析
    Linamar Corporation (LNR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • 3i Group Plc：企業のM&A・事業提携・投資動向
    3i Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's 3i Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Foxconn Technology Co Ltd：企業の戦略・SWOT・財務分析
    Foxconn Technology Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Foxconn Technology Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • SuperSonic Imagine SA (SSI)：企業の財務・戦略的SWOT分析
    Summary SuperSonic Imagine SA (SuperSonic) operates as a medical device company that develops and supplies ultrasound medical imaging systems for measuring and visualizing tissue elasticity. The company offers an ultrasound system, Aixplorer that finds clinical applications in breast, abdomen, liver …
  • Progress Software Corp (PRGS)：企業の財務・戦略的SWOT分析
    Progress Software Corp (PRGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • French National Institute of Health and Medical Research-医療機器分野：企業M&A・提携分析
    Summary French National Institute of Health and Medical Research (INSERM) is a biomedical research institute that conducts research in biology, medicine and public health. The institute offers research in the therapeutic areas of neurosciences, cognitive sciences, neurology, psychiatry, cancer, immu …
  • Korea National Oil Corporation-石油・ガス分野：企業M&A・提携分析
    Summary Korea National Oil Corporation (KNOC) is a state-owned integrated energy company that carries out the exploration, development and production of oil and gas, and stockpiling of petroleum resources. The company purchases and sells crude oil, distribute gasoline and gasoline oil and sells refi …
  • Intersil Corporation (ISIL)：企業の財務・戦略的SWOT分析
    Intersil Corporation (ISIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • MAEC-Kazatomprom LLP：企業の戦略的SWOT分析
    MAEC-Kazatomprom LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Advanced Biological Laboratories SA-製薬・医療分野：企業M&A・提携分析
    Summary Advanced Biological Laboratories SA (ABL) is a healthcare information technology company that provides integrated software solutions for personalised medicine. The company’s products include improving disease management software, project management software, cumulative reporting and related …
  • Medherant Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Medherant Ltd (Medherant) is a transdermal drug delivery patch company. The company develops and commercializes novel technologies for delivery of drugs through the skin using expertise in bioadhesives and polymer chemistry to treat pain, Alzheimer's disease, and for smoking cessation, hormo …
  • American Bridge Company：企業の戦略・SWOT・財務情報
    American Bridge Company - Strategy, SWOT and Corporate Finance Report Summary American Bridge Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • BioCat GmbH-医療機器分野：企業M&A・提携分析
    Summary BioCat GmbH (BioCat) is a medical device company that markets innovative products and services for life science research. The company provides products such as antibodies, epigenetics, PCR, cloning, viral systems, tissue-specific analysis, reporter assays, diabetes, fluorescent proteins, sam …
  • Constellation Pharmaceuticals Inc (CNST)：企業の財務・戦略的SWOT分析
    Constellation Pharmaceuticals Inc (CNST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Equity Residential：企業の戦略・SWOT・財務情報
    Equity Residential - Strategy, SWOT and Corporate Finance Report Summary Equity Residential - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Taconic Biosciences Inc-医療機器分野：企業M&A・提携分析
    Summary Taconic Biosciences Inc (Taconic), formerly Taconic Farms Inc is a research model provider that offers animal health models and laboratory services. The company’s products include taconic transgenic models, emerging models, knockout repository, GEM collection, traditional models, diet induce …
  • Knoll, Inc.：戦略・SWOT・企業財務分析
    Knoll, Inc. - Strategy, SWOT and Corporate Finance Report Summary Knoll, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Seiko Optical Products Co Ltd：企業の戦略的SWOT分析
    Seiko Optical Products Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆